EUVIMEDOpdag EUVIMED
Crossref

Treating Donation After Circulatory Death Liver Grafts With Alteplase During Ex Situ Normothermic Machine Perfusion

Rachel Todd iD, Leonie van Leeuwen iD, Andrew Rosowicz, Aritz Irizar iD, Antonios Arvelakis iD, Joseph DiNorcia iD, Marcelo Facciuto iD, Jang Moon iD, Chiara Rocha iD, Parissa Tabrizian iD, Leona Kim-Schluger iD, Sander S Florman iD and 1 more

Clinical Transplantation · 2025-08 · 39 (8)

DOI: 10.1111/ctr.70282 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2025-08-20. Written by Rachel Todd and 12 co-authors. Institution: Recanati/Miller Transplantation Institute, The Mount Sinai Hospital, New York, New York, USA. Major MEDLINE topics: Liver Transplantation, Tissue Plasminogen Activator, Perfusion, Organ Preservation. Cited 3 times so far (Crossref); 53 references. Funded by: ASTS Veloxis Fellowship in Transplantation, American Society of Transplant Surgeons, Blavatnik Family Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Normothermic machine perfusion (NMP) is increasing the safe utilization of donation after circulatory death livers. Historically, tissue plasminogen activator (tPA) has been administered intraoperatively to DCD graft recipients to reduce non‐anastomotic biliary complications (NAS). Treating the liver during NMP offers a potentially safer administration, preventing systemic treatment of the recipient. In this retrospective study, we explore our center's experience of giving tPA with FFP during NMP and its effects on clinical chemistries during perfusion, intraoperative transfusions, and post‐operative outcomes and clinical chemistries.

Methods

One hundred and twenty‐seven livers were perfused using the OrganOx metra , including 56 DCD livers (tPA + NMP‐DCD) that received a bolus of 10 mg tPA followed by a 90‐min infusion of 40 mg. Sixty‐five livers from donation after brain death donors underwent NMP without tPA (NMP‐DBD). A historical, propensity‐matched cohort of 78 livers from non‐NMP DCD donor livers ( n = 51) were an additional comparator group (tPA‐DCD).

Results

Intraoperative transfusions, 30‐day and 3‐month patient survival, and 30‐day and 3‐month graft survival were not statistically different between the tPA‐NMP‐DCD and NMP‐DBD groups, except for cell saver volumes ( p = 0.0034). Less platelets and cryoprecipitate transfusions were observed in the tPA‐NMP‐DCD livers compared to historical tPA‐DCD livers ( p = 0.0021 and 0.0046, respectively). One incidence of primary non‐function occurred in the tPA‐DCD group, and the tPA‐NMP‐DCD arm had one case of ischemic cholangiopathy required re‐transplant. There was a higher reoperation rate for hematoma evacuation in the NMP‐DBD cohort. Minimum follow‐up time was 5 months.

Conclusion

Our results continue to lend support to NMP providing a platform for administering tPA to donor livers, curtailing a potential risk to the recipient. Summary Administration of tissue plasminogen activator (tPA) can be safely administered during normothermic machine perfusion. For centers who traditionally deploy tPA in recipients for DCD donor livers, delivering during NMP is an alternative safer option sparing the reciepient from exposure.

Subjects

MeSH terms (MEDLINE)

Liver TransplantationTissue Plasminogen ActivatorPerfusionOrgan PreservationTissue DonorsFibrinolytic AgentsTissue and Organ ProcurementPostoperative ComplicationsGraft RejectionHumansFemaleRetrospective StudiesMaleMiddle AgedGraft SurvivalFollow-Up StudiesAdultPrognosisRisk FactorsSurvival Rate

Author keywords

bile ductsdonation after circulatory deathintrahepaticintraoperative transfusionsischemic cholangiopathyliver transplantationnon‐anastomotic stricturenormothermic machine perfusionorgan preservation

Substances

Tissue Plasminogen ActivatorFibrinolytic Agents

Authors and institutions

  • Recanati/Miller Transplantation Institute, The Mount Sinai Hospital, New York, New York, USA.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID profiles: Rachel Todd, Leonie van Leeuwen, Aritz Irizar, Antonios Arvelakis, Joseph DiNorcia, Marcelo Facciuto, Jang Moon, Chiara Rocha, Parissa Tabrizian, Leona Kim-Schluger, Sander S Florman, M Zeeshan Akhtar

Funding

  • ASTS Veloxis Fellowship in Transplantation
  • American Society of Transplant Surgeons
  • Blavatnik Family Foundation

Cite

APA

Todd, R., van Leeuwen, L., Rosowicz, A., Irizar, A., Arvelakis, A., DiNorcia, J., Facciuto, M., Moon, J., Rocha, C., Tabrizian, P., Kim-Schluger, L., Florman, S. S., & Akhtar, M. Z. (2025). Treating Donation After Circulatory Death Liver Grafts With Alteplase During Ex Situ Normothermic Machine Perfusion. Clinical Transplantation, 39(8). https://doi.org/10.1111/ctr.70282

Vancouver

Todd R, van Leeuwen L, Rosowicz A, Irizar A, Arvelakis A, DiNorcia J, et al. Treating Donation After Circulatory Death Liver Grafts With Alteplase During Ex Situ Normothermic Machine Perfusion. Clinical Transplantation. 2025;39(8). doi:10.1111/ctr.70282

BibTeX
@article{Todd2025,
  author = {Todd, Rachel and van Leeuwen, Leonie and Rosowicz, Andrew and Irizar, Aritz and Arvelakis, Antonios and DiNorcia, Joseph and Facciuto, Marcelo and Moon, Jang and Rocha, Chiara and Tabrizian, Parissa and Kim-Schluger, Leona and Florman, Sander S and Akhtar, M Zeeshan},
  title = {Treating Donation After Circulatory Death Liver Grafts With Alteplase During Ex Situ Normothermic Machine Perfusion},
  journal = {Clinical Transplantation},
  year = {2025},
  volume = {39},
  number = {8},
  doi = {10.1111/ctr.70282}
}
Start for free →